传染性法氏囊病不同代次细胞毒免疫效果的研究

将从山东省东营分离到的1株传染性法氏囊病病毒(IBDV)野毒(暂命名IBDV SDDY株,经鉴定该株与IBDV STC株具有较高的同源性)经SPF鸡胚传代,然后转为细胞培养,取第20代、21代、25代毒,以1倍剂量(3000TCID50/0.2mL)和5倍剂量不同的免疫剂量,分别在7日龄、14日龄对商品代海蓝褐蛋鸡进行免疫,并于免疫前用IBD-ELISA试剂盒检测IBDV母源抗体水平,于35日龄用传染性法氏囊病病毒超强毒(very virulent Infectious Bursal Disease Virus,vvIBDV)GX 8/99攻毒,在攻毒前再次检测IBDV的抗体水平,攻毒后观察记录各分组鸡的致病率和死亡率,并计算免疫器官体重指数,观察免疫器官的组织损伤情况.试验结果表明3代毒都具有较高免疫原性,但是20代毒仍具有较大的毒性,7日龄接种会引起法氏囊的萎缩,造成持续的组织损伤;21代毒、25代毒保护率高,无免疫抑制,是比较理想的疫苗来源;7日龄免疫较14日龄免疫更易造成组织损伤和免疫抑制,14日龄免疫较为合适.     

禽呼肠孤病毒感染对鸡法氏囊及免疫应答的影响

研究LY株禽呼肠孤病毒(ARV)感染1日龄SPF鸡后对法氏囊发育影响,对传染性法氏囊病毒(IBDV)、禽流感病毒(AIV)、新城疫病毒(NDV)疫苗免疫诱发的抗体的影响,及对强毒株IBDV致病作用的影响。结果表明,LY株ARV感染1日龄SPF鸡可引起法氏囊萎缩和部分淋巴细胞减少,但对增重及AIV和NDV疫苗免疫后抗体滴度却没有显著影响。ARV感染可降低弱毒IBDV疫苗免疫后的抗体反应,但对随后IBDV强毒株攻毒的抵抗力却与对照鸡无显著差异。经IBDV弱毒疫苗免疫后,再接种强毒株IBDV,不会引起死亡,但却仍能显著抑制对AIV、NDV疫苗免疫后的抗体滴度。然而,对于1~7日龄经ARV感染的鸡,IBDV强毒的这种免疫抑制作用又显著低于未经ARV感染的对照鸡。     

表达IBDV VP2融合蛋白的重组MDV的构建及其免疫特性

将增强型绿色荧光蛋白基因(eGFP)与鸡传染性法氏囊病病毒(IBDV)的VP2基因融合,插入马立克氏病毒(MDV)CVI988/Rispens的非必需区US10片段中,成功构建表达VP2融合蛋白的MDVCVI988转移载体pUC18-US10-VP2。将转移载体质粒与CVI988/Rispens疫苗毒共转染鸡胚成纤维细胞(CEF),筛选获得表达VP2融合蛋白的重组MDV(rMDV)。聚合酶链式反应(PCR)和间接免疫荧光实验(IFA)证明,rMDV传至第31代仍能稳定表达VP2融合蛋白。用rMDV免疫SPF鸡,进行IBDV攻毒保护试验,1日龄SPF鸡分别用1000PFU、2000PFU、5000PFU的rMDV进行免疫,33日龄用100LD50的IBDVJS超强毒进行攻毒,鸡的免疫保护率分别为50%、60%、80%。值得注意的是,5000PFU的rMDV一次免疫1日龄SPF鸡,其法氏囊组织病理损伤等级与IBD中等毒力活疫苗常规二次免疫相当(2·0/1·5),其保护效果无显著差异(p>0·05),而与非重组病毒免疫组相比较,保护效果差异显著(P<0·01),这表明构建的表达IBDVVP2融合蛋白的rMDV可以有效地为SPF鸡提供免疫保护作用。     

鸽副黏病毒Ⅰ型(川沙株)攻毒剂量研究

为了确定鸽副黏病毒Ⅰ型灭活疫苗(S-1株)攻毒试验的攻毒剂量。本研究采用SPF鸡胚测定鸽副黏病毒Ⅰ型强毒株(川沙株)E5代的病毒含量,并以不同剂量病毒液分别接种30日龄低抗体幼龄鸽(HI抗体≤2)和120日龄低抗体青年鸽(HI抗体≤2),对试验鸽进行临床症状和病理学检查。结果显示,该病毒株对低抗体鸽有致死作用,最小致死量为102.5 ELD50。因此,为了确保攻毒效果,在鸽副黏病毒Ⅰ型灭活疫苗(S-1株)制造及检验规程中规定:以1 000倍的最小致死量(即105.5 ELD50)作为疫苗免疫效力检验的攻毒剂量。     

鸡传染性法氏囊病病毒超强毒株GX8/99株的致病性

鸡传染性法氏囊病病毒(IBDV)超强毒株GX8/99,系1999年从广西一自然发病鸡群采集到.用原始病鸡法氏囊悬液连续3次人工感染SPF鸡后,再取其法氏囊制备悬液,分装,在-70℃保存.以此悬液经卵黄囊接种10日龄SPF鸡胚,测定鸡胚的半数致死量(ELD50).随着鸡的日龄和接种剂量的不同,其致死率有很大差异.对28～30日龄SPF鸡,病毒接种量为200个ELD50时,感染后7日内死亡率最高可达73%～90.5%(11/15和19/21);感染量为20个ELD50时,死亡率亦可达53%～92%(8/15和23/25).以500个ELD50感染28～104日龄的SPF鸡,死亡率均在55.1%～67.2%;甚至113～120日龄的SPF鸡,感染后仍有10%～15%致死率.但128日龄的SPF鸡感染后既不引起死亡也不表现任何症状,但抗体全部转阳.人工接种发病死亡的鸡,其法氏囊的出血程度也随感染量和年龄而异.50日龄鸡接种2000个ELD50后,死亡的鸡100%(12/12)法氏囊严重出血;而40日龄鸡感染200个ELD50后,死亡鸡中仅17%(3/18)发生出血.在2、3、4周龄带有母源抗体的商品代蛋鸡,以2000个ELD50病毒接种后,只引起10%(2/20)、35%(7/20)和35%(7/20)的死亡率.但在5周龄商品代蛋鸡,仅接触感染的致死率可达61.3%(98/160).另一批商品代蛋鸡,在4周龄和5周龄人工接种200个ELD50病毒后,死亡率分别是81.6%～94.3%(62/76～33/35)和93.9%～94%(31/33～47/50).通过总共1200多羽鸡的试验表明,GX-8/99株是一个超强毒IBDV毒株,表现为高死亡率(最高可达94%),易感年龄延长至4月龄,中枢性免疫器官法氏囊出血严重和胸腺明显萎缩.     

蛹虫草基质多糖对鸡传染性支气管炎灭活疫苗的免疫佐剂作用

以蛹虫草基质多糖为免疫佐剂,将其混入传染性支气管炎灭活疫苗,从而探讨其对肉仔鸡的免疫功能影响。选用150只1日龄黄羽肉鸡,随机分成5组。免疫后21 d(35日龄)采用IBV M41株病毒液进行点眼、滴鼻攻毒。通过测定每组的鸡淋巴细胞(PBMC)增殖情况、鸡血清抗体效价、IBV强毒株攻毒保护及组织病理学变化。结果表明,蛹虫草基质多糖中剂量佐剂组的鸡淋巴细胞(PBMC)增殖指数、鸡血清抗体效价水平有着显著提高(P0.05),在IBV M41株攻毒试验中,蛹虫草基质多糖中剂量佐剂组可以显著减轻病毒感染肉仔鸡临床症状,肺和肾无组织病理学变化,免疫保护率达到96.7%。表明以蛹虫草基质多糖佐剂能够提高肉仔鸡对传染性支气管炎的免疫力。     

表达鸡传染性法氏囊病毒VP2蛋白的干酪乳杆菌免疫保护效力

利用干酪乳杆菌作为传染性法氏囊病毒(IBDV)VP2抗原传递系统,探讨口服雏鸡的免疫次数、免疫剂量、免疫途径和攻毒保护效果。用pLA-VP2重组干酪乳杆菌对5日龄雏鸡进行二次和三次免疫,并设108、109、1010 CFU/mL的重组干酪乳杆菌组,间接ELISA检测血清IgG和小肠洗液sIgA,末免后7 d攻毒,计算保护效果。根据确定的2次免疫和109 CFU/mL免疫剂量免疫5日龄雏鸡,分别口服、滴鼻/点眼pLA-VP2/L.casei,口服、肌注商品活苗及口服pLA/L.casei和PBS为对照,监测IgG和sIgA抗体水平;末免后7 d检测脾淋巴细胞增殖情况并攻毒,7 d后剖检,观察法氏囊损伤程度并记录病变得分和保护率。结果表明各组的特异性sIgA、IgG抗体水平显著高于对照组(P0.01);口服pLA-VP2/L.casei组的淋巴细胞刺激指数显著高于其他组(P0.01),保护率高达83.3%,免疫保护效果优于滴鼻/点眼组。因此,构建的重组干酪乳杆菌的安全性优于商品活苗,可以作为IBDV候选疫苗。     

传染性法氏囊病病毒反向遗传技术发展及其应用

传染性法氏囊病病毒(Infectious bursal disease virus,IBDV)是双股双节段RNA病毒科的主要代表,其主要侵害鸡的中枢免疫器官法氏囊,引起的传染性法氏囊病(Infectious bursal disease,IBD)是危害养禽业健康发展的重要免疫抑制病。IBDV反向遗传技术诞生的近20年来,病毒拯救技术不断完善,病毒基因功能研究更为深入,而且基于此的新型疫苗的研究也有较大进展。本实验室在该领域也做了比较系统和深入的工作。本综述对IBDV致病机制和防控研究具有重要启示意义。     

鸡白细胞介素2增强传染性法氏囊病病毒多聚蛋白DNA疫苗免疫原性的研究

鸡白细胞介素 2(IL-2)基因是新近被确定的非哺乳类IL-2基因。将鸡白细胞介素2(IL-2)基因和传染性法氏囊病病毒 (IBDV)多聚蛋白基因 (VP2/VP4/VP3)分别插入真核表达载体pCI的CMV启动子下游 ,制备DNA疫苗 ,免疫 14日龄SPF鸡 ,14d后二免 ,二免后 3d攻击标准强毒株。结果表明共注射鸡IL 2质粒能明显增强DNA疫苗对强毒攻击 ,保护率达 80 % ;能增强DNA疫苗诱导的中和抗体效价 (P<0.05 ) ;能显著促进鸡胸腺、脾脏和外周血液T淋巴细胞及法氏囊B淋巴细胞增殖反应(P<0.05)。这些结果提示鸡IL 2能明显增强IBDV多聚蛋白DNA疫苗的免疫原性 ,是一种优良的禽类DNA疫苗佐剂。     

传染性法氏囊病病毒分子生物学研究进展

传染性法氏囊病病毒(Infectious bursal disense virus,IBDV)是引起鸡的最严重的传染病之一,给养鸡业造成了巨大的经济损失,其危害除了直接引起临床症状外,更为重要的是破坏机体的免疫器官,主要是破坏B淋巴细胞前体,引起严重的免疫抑制,使鸡对其他病原的免疫力丧失,结果导致死亡。 IBDV最初被认为是呼肠孤病毒科的成员,主要是因为其在鸡胚肾细胞上培养出现     

传染性法氏囊病病毒多表位模拟肽串联基因的表达与免疫原性分析

用5株传染性法氏囊病病毒(IBDV)单克隆抗体(mAb)从噬菌体随机肽库中得到了5个含有不同IBDV抗原表位的模拟肽序列。在此基础上,将5个抗原表位用GGGS四肽连接构建多表位基因5epis。将该基因合成、克隆后,构建原核表达质粒pET-5epis,在大肠杆菌中表达重组多表位蛋白r5EPIS,经SDS-PAGE分析,r5EPIS占菌体总蛋白的15%、分子量10kDa。用IBDV单克隆抗体和多克隆抗体对r5EPIS进行免疫印迹对比分析,结果表明,r5EPIS具有IBDV特异性和免疫反应性。将r5EPIS经皮下注射免疫兔,400μg/只/次,免疫2次,间隔7d,用IBDV间接ELISA检测血清抗体,第一次免疫7d后抗体效价为1∶4000,第二次免疫14d后抗体效价升高到1∶256000,说明r5EPIS可诱导机体产生IBDV特异性抗体。用r5EPIS加免疫佐剂经肌肉注射免疫鸡,50μg/只/次,免疫2次后,血清抗体效价可达到1∶12800,用200个ELD50IBDV超强毒株GX8/99攻击实验鸡,r5EPIS免疫组全部存活,而单用佐剂对照组的死亡率为86.7%(13/15),证明r5EPIS可诱导机体产生抗IBDV感染的保护性免疫应答,预示构建的5epis可作为IBD多表位疫苗研究的候选基因。     

Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens

Marek's disease herpesvirus is a vaccine vector of great promise for chickens; however, complete protection against foreign infectious diseases has not been achieved. In this study, two herpesvirus of turkey recombinants (rHVTs) expressing large amounts of infectious bursal disease virus (IBDV) VP2 antigen under the control of a human cytomegalovirus (CMV) promoter or CMV/beta-actin chimera promoter (Pec promoter) (rHVT-cmvVP2 and rHVT-pecVP2) were constructed. rHVT-pecVP2, which expressed the VP2 antigen approximately four times more than did rHVT-cmvVP2 in vitro, induced complete protection against a lethal IBDV challenge in chickens, whereas rHVT-cmvVP2 induced 58% protection. All of the chickens vaccinated with rHVT-pecVP2 had a protective level of antibodies to the VP2 antigen at the time of challenge, whereas only 42 and 67% of chickens vaccinated with rHVT-cmvVP2 or the conventional live IBDV vaccine, respectively, had the antibodies. The antibody level of chickens vaccinated with rHVT-pecVP2 increased for 16 weeks, and the peak antibody level persisted throughout the experiment. The serum antibody titer at 30 weeks of age was about 20 or 65 times higher than that of chickens vaccinated with rHVT-cmvVP2 or the conventional live vaccine, respectively. rHVT-pecVP2, isolated consistently for 30 weeks from the vaccinated chickens, expressed the VP2 antigen after cultivation, and neither nucleotide mutations nor deletion in the VP2 gene was found. These results demonstrate that the amount of VP2 antigen expressed in the HVT vector was correlated with the vaccine efficacy against lethal IBDV challenge, and complete protective immunity that is likely to persist for the life of the chickens was induced.     

Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis

Human cytomegalovirus (HCMV) possesses low pathogenic potential in an immunocompetent host. In the immunosuppressed host, however, a wide spectrum of infection outcomes, ranging from asymptomatic to life threatening, can follow either primary or nonprimary infection. The variability in the manifestations of HCMV infection in immunosuppressed individuals implies that there is a threshold of host antiviral immunity that can effectively limit disease potential. We used a nonhuman primate model of CMV infection to assess the relationship between CMV disease and the levels of developing anti-CMV immunity. Naive rhesus macaques were inoculated with rhesus cytomegalovirus (RhCMV) followed 2 or 11 weeks later by inoculation with pathogenic simian immunodeficiency virus SIVmac239. Two of four monkeys inoculated with SIV at 2 weeks after inoculation with RhCMV died within 11 weeks with simian AIDS (SAIDS), including activated RhCMV infection. Neither animal had detectable anti-SIV antibodies. The other two animals died 17 and 27 weeks after SIV inoculation with either SAIDS or early lymphoid depletion, although no histological evidence of activated RhCMV was observed. Both had weak anti-SIV antibody titers. RhCMV antibody responses for this group of monkeys were significantly below those of control animals inoculated with only RhCMV. In addition, all animals of this group had persistent RhCMV DNA in plasma and high copy numbers of RhCMV in tissues. In contrast, animals that were inoculated with SIV at 11 weeks after RhCMV infection rarely exhibited RhCMV DNA in plasma, had low copy numbers of RhCMV DNA in most tissues, and did not develop early onset of SAIDS or activated RhCMV. SIV antibody titers were mostly robust and sustained in these monkeys. SIV inoculation blunted further development of RhCMV humoral responses, unlike the normal pattern of development in control monkeys following RhCMV inoculation. Anti-RhCMV immunoglobulin G levels and avidity were slightly below control values, but levels maintained were higher than those observed following SIV infection at 2 weeks after RhCMV inoculation. These findings demonstrate that SIV produces long-lasting insults to the humoral immune system beginning very early after SIV infection. The results also indicate that anti-RhCMV immune development at 11 weeks after infection was sufficient to protect the host from acute RhCMV sequelae following SIV infection, in contrast to the lack of protection afforded by only 2 weeks of immune response to RhCMV. As previously observed, monkeys that were not able to mount a significant immune response to SIV were the most susceptible to SAIDS, including activated RhCMV infection. Rapid development of SAIDS in animals inoculated with SIV 2 weeks after RhCMV inoculation suggests that RhCMV can augment SIV pathogenesis, particularly during primary infection by both viruses.     

Effects of hydrostatic pressure on the structure and biological activity of infectious bursal disease virus.

The effects of high hydrostatic pressure on the structure and biological activity of infectious bursal disease virus (IBDV), a commercially important pathogen of chickens, were investigated. IBDV was completely dissociated into subunits at a pressure of 240 MPa and 0 degrees C revealed by the change in intrinsic fluorescence spectrum and light scattering. The dissociation of IBDV showed abnormal concentration dependence as observed for some other viruses. Electron microscopy study showed that morphology of IBDV had an obvious change after pressure treatment at 0 degrees C. It was found that elevating pressure destroyed the infectivity of IBDV, and a completely pressure-inactivated IBDV could be obtained under proper conditions. The pressure-inactivated IBDV retained the original immunogenic properties and could elicit high titers of virus neutralizing antibodies. These results indicate that hydrostatic pressure provides a potential physical means to prepare antiviral vaccine.     

Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin.

Inoculation of mice with hemagglutinin (HA)-expressing DNA affords reliable protection against lethal influenza virus infection, while in chickens the same strategy has yielded variable results. Here we show that gene gun delivery of DNA encoding an H5 HA protein confers complete immune protection to chickens challenged with lethal H5 viruses. In tests of the influence of promoter selection on vaccine efficacy, close correlations were obtained between immune responses and the dose of DNA administered, whether a cytomegalovirus (CMV) immediate-early promoter or a chicken beta-actin promoter was used. Perhaps most important, the HA-DNA vaccine conferred 95% cross-protection against challenge with lethal antigenic variants that differed from the primary antigen by 11 to 13% (HA1 amino acid sequence homology). Overall, the high levels of protection seen with gene gun delivery of HA-DNA were as good as, if not better than, those achieved with a conventional whole-virus vaccine, with fewer instances of morbidity and death. The absence of detectable antibody titers after primary immunization, together with the rapid appearance of high titers immediately after challenge, implicates efficient B-cell priming as the principal mechanism of DNA-mediated immune protection. Our results suggest that the efficacy of HA-DNA influenza virus vaccine in mice extends to chickens and probably to other avian species as well. Indeed, the H5 preparation we describe offers an attractive means to protect the domestic poultry industry in the United States from lethal H5N2 viruses, which continue to circulate in Mexico.     

Analyzing the H19- and T65-epitopes in 38 kd phosphory-lated protein of Marek’s disease viruses and comparing chicken immunological reactions to viruses point-mutated in the epitopes

DNA sequencing analysis in 38 kd phosphorylated protein (pp38) ORF of Marek's disease viruses (MDV) indicated that all tested 10 virulent strains with different pathotypes had 'A' at base #320 and glutamine at aa#107 while reacted with monoclonal antibody (Mab) H19 in indirect fluorescence antibody test (IFA). However, vaccine strain CVI988 had 'G' at base#320 and arginine at aa#107 instead, when it was negative in IFA with Mab H19. Some strains were also reactive with Mab T65 in IFA while there was 'G' at base #326 and glycine at aa#109, but the other strains, which had 'A' at base #326 and glutamic acid at aa#109, did not react with Mab T65. By comparison of CVI988 to its point mutants CVI/rpp38(AG) and CVI/rpp38(AA) with 1 or 2 base(s) changes at bases #320 and /or #326 of pp38 gene for their reactivity with Mab H19 and T65, it was confirmed that the glutamine at aa#107 and glycine at aa#109 were critical to epi-topes H19 and T65 respectively. Immuno-reactions to MDV were compared in SPF chickens ino     

Comparison of dimethyl dioctadecyl ammonium bromide, Freund's complete adjuvant and mineral oil for induction of humoral antibodies, cellular immunity and resistance to Newcastle disease virus in chickens

Abstract Dimethyl diotadecyl ammonium bromide (DDA), a lipophilic quaternary amine, was evaluated in adult chickens for potentiation of immunological responses to subcutaneously administered inactivated Newcastle disease virus (NDV) vaccines. DDA enhanced humoral and cell-mediated immune (CMI) responses to levels which were significantly higher than those induced by the vaccine alone The haemagglutination inhibition antibody titers induced by DDA were slightly lower than those induced by mineral oil although neutralizing antibody titers seemed to be higher. DDA induced strong CMI (DTH and lymphocyte proliferation) responses, more than those induced by Freund's complete adjuvant and mineral oil. Both DDA and mineral oil induced comparable high levels of protection to challenge doses of 200 000 LD₅₀ per chicken. No toxic effects or local tissue damage were observed in any of the inoculated chickens.